600771 广誉远
已收盘 06-30 15:00:00
资讯
新帖
简况
广誉远(600771)披露2025年年度股东会法律意见书,6月29日股价上涨5.27%
证券之星 · 06-29 22:43
广誉远(600771)披露2025年年度股东会法律意见书,6月29日股价上涨5.27%
广誉远:公司已于2023年实现扭亏为盈
证券之星 · 06-26
广誉远:公司已于2023年实现扭亏为盈
广誉远:所有诉讼案件均严格按照披露标准进行披露
证券之星 · 06-26
广誉远:所有诉讼案件均严格按照披露标准进行披露
广誉远:西黄丸、感冒清热颗粒尚未形成规模化销售
证券之星 · 06-26
广誉远:西黄丸、感冒清热颗粒尚未形成规模化销售
广誉远:公司始终坚定聚焦中药主责主业
证券之星 · 06-26
广誉远:公司始终坚定聚焦中药主责主业
每周股票复盘:广誉远(600771)西黄丸等产品中选全国集采
证券之星 · 06-20
每周股票复盘:广誉远(600771)西黄丸等产品中选全国集采
广誉远最新公告:西黄丸和感冒清热颗粒中选全国中成药集采
证券之星 · 06-18
广誉远最新公告:西黄丸和感冒清热颗粒中选全国中成药集采
广誉远(600771)披露2025年年度股东会会议资料,6月17日股价下跌1.37%
证券之星 · 06-17
广誉远(600771)披露2025年年度股东会会议资料,6月17日股价下跌1.37%
广誉远:任何涉及财务账务的处理都是严格基于企业会计准则及相关会计政策要求的常规会计处理
证券之星 · 06-15
广誉远:任何涉及财务账务的处理都是严格基于企业会计准则及相关会计政策要求的常规会计处理
广誉远:公司已及时、完整披露案件相关进展
证券之星 · 06-15
广誉远:公司已及时、完整披露案件相关进展
广誉远:龟龄集酒基酒采用公司自产清香型白酒
证券之星 · 06-15
广誉远:龟龄集酒基酒采用公司自产清香型白酒
广誉远:龟龄集是药品,药品就会有对应的症候和适应症
证券之星 · 06-15
广誉远:龟龄集是药品,药品就会有对应的症候和适应症
广誉远:公司产品直播营销仅限于持证经营主体自营直播间开展
证券之星 · 06-15
广誉远:公司产品直播营销仅限于持证经营主体自营直播间开展
广誉远:公司正视与行业内优秀老字号企业在营收规模、盈利水平、运营效率等方面的差距
证券之星 · 06-11
广誉远:公司正视与行业内优秀老字号企业在营收规模、盈利水平、运营效率等方面的差距
广誉远:公司经营质量已显著改善
证券之星 · 06-11
广誉远:公司经营质量已显著改善
广誉远:关于定增注入农业资产事宜,公司已明确澄清,始终聚焦中医药主责主业,无此类计划
证券之星 · 06-11
广誉远:关于定增注入农业资产事宜,公司已明确澄清,始终聚焦中医药主责主业,无此类计划
广誉远:公司一方面持续聚焦主业发展,优化经营管理,推进产品市场拓展,不断夯实经营基本面
证券之星 · 06-11
广誉远:公司一方面持续聚焦主业发展,优化经营管理,推进产品市场拓展,不断夯实经营基本面
广誉远:公司近两年营业收入、利润总额、经营性现金流、销售费用率、应收账款等核心指标均在持续改善中
证券之星 · 06-11
广誉远:公司近两年营业收入、利润总额、经营性现金流、销售费用率、应收账款等核心指标均在持续改善中
每周股票复盘:广誉远(600771)完成回购耗资近5000万元
证券之星 · 06-07
每周股票复盘:广誉远(600771)完成回购耗资近5000万元
广誉远:关于使用公积金弥补亏损的议案
证券之星 · 06-05
广誉远:关于使用公积金弥补亏损的议案
加载更多
公司概况
公司名称:
广誉远中药股份有限公司
所属行业:
医药制造业
上市日期:
1996-11-05
主营业务:
广誉远中药股份有限公司的主营业务是中药产品的生产与销售。公司的主要产品是龟龄集、定坤丹大蜜丸、定坤丹水蜜丸、定坤丹口服液、安宫牛黄丸、牛黄清心丸、加味龟龄集酒、远字牌龟龄集酒。公司产品先后获得“山西精品”认定,六味地黄丸传统制作技艺及姜炭制作技艺入选晋中市非物质文化遗产名录。
发行价格:
4.80
{"stockData":{"symbol":"600771","market":"SH","secType":"STK","nameCN":"广誉远","latestPrice":12.95,"timestamp":1782802801000,"preClose":13.38,"halted":0,"volume":7266755,"delay":0,"changeRate":-0.0321,"floatShares":488999999,"shares":488999999,"eps":0.1353,"marketStatus":"已收盘","change":-0.43,"latestTime":"06-30 15:00:00","open":13.35,"high":13.4,"low":12.86,"amount":94823100,"amplitude":0.0404,"askPrice":12.97,"askSize":40,"bidPrice":12.95,"bidSize":35,"shortable":0,"etf":0,"ttmEps":0.1353,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1782869400000},"marketStatusCode":5,"adr":0,"adjPreClose":13.38,"symbolType":"stock","openAndCloseTimeList":[[1782783000000,1782790200000],[1782795600000,1782802800000]],"highLimit":14.72,"lowLimit":12.04,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":489491141,"isCdr":false,"pbRate":3.73,"roa":"--","peRate":95.71323,"roe":"4.01%","epsLYR":0.13,"committee":0.317027,"marketValue":6339000000,"turnoverRate":0.0148,"status":1,"floatMarketCap":6339000000},"requestUrl":"/m/hq/s/600771","defaultTab":"news","newsList":[{"id":"2647088963","title":"广誉远(600771)披露2025年年度股东会法律意见书,6月29日股价上涨5.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647088963","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647088963?lang=zh_cn&edition=full","pubTime":"2026-06-29 22:43","pubTimestamp":1782744195,"startTime":"0","endTime":"0","summary":"截至2026年6月29日收盘,广誉远报收于13.38元,较前一交易日上涨5.27%,最新总市值为65.49亿元。近日,广誉远披露北京海润天睿律师事务所关于公司2025年年度股东会的法律意见书。公告显示,该所确认广誉远中药股份有限公司2025年年度股东会的召集、召开程序、出席会议人员资格、召集人资格、表决程序及表决结果均符合相关法律法规及《公司章程》规定,会议决议合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900041526.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600771","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646733778","title":"广誉远:公司已于2023年实现扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2646733778","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646733778?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:18","pubTimestamp":1782461907,"startTime":"0","endTime":"0","summary":"证券之星消息,广誉远06月26日在投资者关系平台上答复投资者关心的问题。您的“公司仍存在大额亏损”信息并不准确,公司已于2023年实现扭亏为盈,此后也持续保持盈利。当前公司正处于经营修复和深化发展的关键阶段,管理层将持续深耕中药主责主业,全力巩固经营向好态势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600029455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","BK0077","600771"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646337762","title":"广誉远:所有诉讼案件均严格按照披露标准进行披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2646337762","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646337762?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:18","pubTimestamp":1782461907,"startTime":"0","endTime":"0","summary":"针对前述信息披露违法违规事项的相关情况均第一时间公告,依法履行了信息披露义务。公司始终高度重视全体股东的知情权和合法权益,所有诉讼均有专业人员跟进,公司严格及时履行信息披露义务,不存在应披未披事项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600029456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","600771","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646337719","title":"广誉远:西黄丸、感冒清热颗粒尚未形成规模化销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2646337719","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646337719?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:18","pubTimestamp":1782461901,"startTime":"0","endTime":"0","summary":"公司控股子公司山西广誉远国药生产的西黄丸、感冒清热颗粒中选全国中成药集采后,公司正积极推进相关落地执行工作,但该工作受各省集采实施节奏、院内入院流程周期等因素影响,当前两款产品尚未形成规模化销售,此两款产品公司仍采取先款后货销售方式,不会存在应收账款,集采业务对公司2026年度经营业绩影响需以后期实际销售情况为准,存在一定不确定性,请您关注公司后续披露的定期报告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600029442.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600771","BK0077","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646533747","title":"广誉远:公司始终坚定聚焦中药主责主业","url":"https://stock-news.laohu8.com/highlight/detail?id=2646533747","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646533747?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:16","pubTimestamp":1782461766,"startTime":"0","endTime":"0","summary":"证券之星消息,广誉远06月26日在投资者关系平台上答复投资者关心的问题。公司始终坚定聚焦中药主责主业,核心资源持续向龟龄集、定坤丹等四大核心单品投入,核心产品营收占比95%左右。公司始终严控大健康品类的生产和销售,始终坚持资源聚焦核心主业,确保主业战略落地执行,绝非口头表述。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600029168.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600771","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644063220","title":"每周股票复盘:广誉远(600771)西黄丸等产品中选全国集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2644063220","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644063220?lang=zh_cn&edition=full","pubTime":"2026-06-20 02:20","pubTimestamp":1781893221,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘,广誉远报收于13.49元,较上周的14.1元下跌4.33%。本周,广誉远6月15日盘中最高价报14.33元。本周关注点来自公司公告汇总:广誉远控股子公司西黄丸和感冒清热颗粒中选全国中成药集采。来自公司公告汇总:2025年广誉远实现营业收入13.69亿元,同比增长12.11%。广誉远中药股份有限公司控股子公司山西广誉远国药有限公司生产的西黄丸和感冒清热颗粒,参加全国中成药采购联盟集中带量采购并直接中选。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062000000657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","600771","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644079701","title":"广誉远最新公告:西黄丸和感冒清热颗粒中选全国中成药集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2644079701","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644079701?lang=zh_cn&edition=full","pubTime":"2026-06-18 17:42","pubTimestamp":1781775740,"startTime":"0","endTime":"0","summary":"广誉远(600771.SH)公告称,公司控股子公司山西广誉远生产的西黄丸和感冒清热颗粒两款产品首次进入集采体系,且在本次全国中成药采购联盟集中带量采购中直接中选。上述产品2025年度及2026年第一季度销售收入极低,预计本次集采中选价格不会对公司现有存量业务的毛利率及当期利润产生重大不利影响。采购周期自中选结果实际执行之日起至2028年12月31日。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061800031627.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","600771","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644426147","title":"广誉远(600771)披露2025年年度股东会会议资料,6月17日股价下跌1.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2644426147","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644426147?lang=zh_cn&edition=full","pubTime":"2026-06-17 22:40","pubTimestamp":1781707226,"startTime":"0","endTime":"0","summary":"截至2026年6月17日收盘,广誉远报收于13.64元,较前一交易日下跌1.37%,最新总市值为66.77亿元。该股当日开盘13.9元,最高13.9元,最低13.58元,成交额达5457.5万元,换手率为0.82%。近日,广誉远中药股份有限公司发布2025年年度股东会会议资料。2025年实现营业收入13.69亿元,同比增长12.11%;利润总额1.03亿元,同比增长27.45%;但因子公司补缴税款影响,归属于上市公司股东的净利润同比下降15.32%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700042405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600771","BK0077","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643271204","title":"广誉远:任何涉及财务账务的处理都是严格基于企业会计准则及相关会计政策要求的常规会计处理","url":"https://stock-news.laohu8.com/highlight/detail?id=2643271204","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643271204?lang=zh_cn&edition=full","pubTime":"2026-06-15 17:30","pubTimestamp":1781515844,"startTime":"0","endTime":"0","summary":"证券之星消息,广誉远06月15日在投资者关系平台上答复投资者关心的问题。对新任领导的需求,理解!广誉远注入上市公司后,由于大股东的原因,到过50多亿!无奈又悲哀广誉远回复:您好,感谢您的关注。任何涉及财务账务的处理,都是严格基于企业会计准则及相关会计政策要求的常规会计处理,基于审慎性原则,客观反应各类资产的当前价值,不会损害公司长期经营利益与核心资产质量。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500022043.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600771","BK0239","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643712012","title":"广誉远:公司已及时、完整披露案件相关进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2643712012","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643712012?lang=zh_cn&edition=full","pubTime":"2026-06-15 17:30","pubTimestamp":1781515843,"startTime":"0","endTime":"0","summary":"证券之星消息,广誉远06月15日在投资者关系平台上答复投资者关心的问题。投资者提问:东盛集团 9.34 亿业绩补偿案 5 月 13 日一审胜诉后,至今未披露上诉、执行、过户等关键进展。关于公司与西安东盛集团之间的诉讼案件,公司已及时、完整披露案件相关进展。后续如若涉及应当披露事项,公司将及时履行信息披露义务,请您持续关注后续公告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500022034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","600771","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643493271","title":"广誉远:龟龄集酒基酒采用公司自产清香型白酒","url":"https://stock-news.laohu8.com/highlight/detail?id=2643493271","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643493271?lang=zh_cn&edition=full","pubTime":"2026-06-15 17:27","pubTimestamp":1781515642,"startTime":"0","endTime":"0","summary":"证券之星消息,广誉远(600771)06月15日在投资者关系平台上答复投资者关心的问题。投资者提问:同为山西国资旗下,汾酒与广誉远酒药协同显著,龟龄集酒基酒采购自汾酒。请问公司是否考虑向汾酒定增引入战投(5%–10%),绑定利益、借力汾酒全国渠道与品牌力,解决新媒体投入不足、动销乏力问题?广誉远回复:您好,感谢您的关注及建议。龟龄集酒基酒采用公司自产清香型白酒。如若涉及相关资本运作事项,公司会依法依规及时披露,请关注公司公告。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500021904.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0239","600771","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643271165","title":"广誉远:龟龄集是药品,药品就会有对应的症候和适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=2643271165","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643271165?lang=zh_cn&edition=full","pubTime":"2026-06-15 17:15","pubTimestamp":1781514935,"startTime":"0","endTime":"0","summary":"去年龟龄集同比增长仅1%,公司是否复盘过营销思路出错的根源?龟龄集是药品,药品就会有对应的症候和适应症,药品最基本的作用是为有健康需求的人群提供服务,任何药品都需要也必须明确治疗价值,而获益人群也就自然明确下来。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500021540.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600771","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643326271","title":"广誉远:公司产品直播营销仅限于持证经营主体自营直播间开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2643326271","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643326271?lang=zh_cn&edition=full","pubTime":"2026-06-15 17:09","pubTimestamp":1781514571,"startTime":"0","endTime":"0","summary":"证券之星消息,广誉远06月15日在投资者关系平台上答复投资者关心的问题。公司产品直播营销仅限于持证经营主体自营直播间开展,同时,公司持续保持对多种传播渠道的关注,积极推进线上曝光与线下成交转化模式联动,持续优化直播运营策略、丰富推广品类与形式,进一步提升品牌曝光与市场转化能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061500021237.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","600771","BK0077","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642402099","title":"广誉远:公司正视与行业内优秀老字号企业在营收规模、盈利水平、运营效率等方面的差距","url":"https://stock-news.laohu8.com/highlight/detail?id=2642402099","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642402099?lang=zh_cn&edition=full","pubTime":"2026-06-11 16:06","pubTimestamp":1781165204,"startTime":"0","endTime":"0","summary":"证券之星消息,广誉远06月11日在投资者关系平台上答复投资者关心的问题。望各位领导们能知耻而后勇,实在做不好也就不要占着位置辜负广大投资者了广誉远回复:您好,感谢您的关注。公司对经营中的阶段性进展始终保持清醒认知,从不“沾沾自喜”,公司正视与行业内优秀老字号企业在营收规模、盈利水平、运营效率等方面的差距,始终以“知不足而奋进”的态度推进各项工作。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100024155.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600771"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642407890","title":"广誉远:公司经营质量已显著改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2642407890","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642407890?lang=zh_cn&edition=full","pubTime":"2026-06-11 16:06","pubTimestamp":1781165184,"startTime":"0","endTime":"0","summary":"证券之星消息,广誉远06月11日在投资者关系平台上答复投资者关心的问题。公司经营质量已显著改善,并积极执行增持、回购等有利于市场价值提升的举措,正以提质增效为核心,聚焦主业深耕细作,全力以赴提升经营质量与业绩表现,回报全体投资者。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100024108.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","600771","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642407894","title":"广誉远:关于定增注入农业资产事宜,公司已明确澄清,始终聚焦中医药主责主业,无此类计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2642407894","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642407894?lang=zh_cn&edition=full","pubTime":"2026-06-11 16:06","pubTimestamp":1781165182,"startTime":"0","endTime":"0","summary":"证券之星消息,广誉远06月11日在投资者关系平台上答复投资者关心的问题。当下唯一能看到公司产品里面可能会有爆发性的就只有保健酒,只有保健酒的爆发还能让广誉远维持住当下的估值,否则必将回归行业均值,尤其是大家诟病的要定增注入农业资产必将让广誉远滑入估值的深渊再无出头之日,请公司领导知悉并重视广誉远回复:您好,感谢您的关注。关于定增注入农业资产事宜,公司已明确澄清,始终聚焦中医药主责主业,无此类计划。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100024103.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","BK0239","600771","159041"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642022974","title":"广誉远:公司一方面持续聚焦主业发展,优化经营管理,推进产品市场拓展,不断夯实经营基本面","url":"https://stock-news.laohu8.com/highlight/detail?id=2642022974","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642022974?lang=zh_cn&edition=full","pubTime":"2026-06-11 15:57","pubTimestamp":1781164633,"startTime":"0","endTime":"0","summary":"证券之星消息,广誉远06月11日在投资者关系平台上答复投资者关心的问题。上市公司市值管理的核心是以提高公司质量为基础,为提升公司投资价值和股东回报能力而实施的战略管理行为。公司一方面持续聚焦主业发展,优化经营管理,推进产品市场拓展,不断夯实经营基本面;另一方面积极推出股份回购、高管增持等各类举措落地,及时传递公司及管理层信心和日常经营动态,全力维护全体股东合法权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100022925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","600771","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642402488","title":"广誉远:公司近两年营业收入、利润总额、经营性现金流、销售费用率、应收账款等核心指标均在持续改善中","url":"https://stock-news.laohu8.com/highlight/detail?id=2642402488","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642402488?lang=zh_cn&edition=full","pubTime":"2026-06-11 15:54","pubTimestamp":1781164459,"startTime":"0","endTime":"0","summary":"证券之星消息,广誉远06月11日在投资者关系平台上答复投资者关心的问题。公司管理层正常履职尽责,公司近两年营业收入、利润总额、经营性现金流、销售费用率、应收账款等核心指标均在持续改善中,公司始终重视并积极开展市值管理及提升经营质量的相关工作,包括但不限于制定行动方案、股份回购、董事及高管增持,拟使用公积金弥补亏损等举措。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100022447.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159399","600771"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641122728","title":"每周股票复盘:广誉远(600771)完成回购耗资近5000万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2641122728","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641122728?lang=zh_cn&edition=full","pubTime":"2026-06-07 01:53","pubTimestamp":1780768390,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘,广誉远报收于14.57元,较上周的15.23元下跌4.33%。本周,广誉远6月1日盘中最高价报15.23元。本周关注点公司公告汇总:广誉远完成股份回购,实际回购金额49,981,344.56元。公司公告汇总广誉远中药股份有限公司于2026年3月26日披露股份回购方案,拟以集中竞价交易方式回购股份,用于员工持股计划或股权激励,回购金额为3,000万元至5,000万元,价格上限为26.09元/股,实施期限为2026年3月27日至9月26日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","600771","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641116760","title":"广誉远:关于使用公积金弥补亏损的议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2641116760","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641116760?lang=zh_cn&edition=full","pubTime":"2026-06-05 17:00","pubTimestamp":1780650047,"startTime":"0","endTime":"0","summary":"证券之星消息,广誉远06月05日在投资者关系平台上答复投资者关心的问题。根据《公司法》《公司章程》及《股东会议事规则》等相关规定,公司2025年度股东会将在上一会计年度结束后的六个月内举行,《关于使用公积金弥补亏损的议案》尚需提交该次股东会审议,公司将严格按规定于会议召开20日前发布会议通知,请您关注后续公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060500028932.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","600771","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1782809175315,"stockEarnings":[{"period":"1week","weight":-0.0052},{"period":"1month","weight":-0.1215},{"period":"3month","weight":-0.2088},{"period":"6month","weight":-0.2558},{"period":"1year","weight":-0.331},{"period":"ytd","weight":-0.2558}],"compareEarnings":[{"period":"1week","weight":-0.0214},{"period":"1month","weight":0.0013},{"period":"3month","weight":0.0468},{"period":"6month","weight":0.0265},{"period":"1year","weight":0.1897},{"period":"ytd","weight":0.0265}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广誉远中药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"65920人(较上一季度增加2.20%)","perCapita":"7425股","listingDate":"1996-11-05","address":"山西省晋中市太谷区广誉远路1号","registeredCapital":"48949万元","survey":" 广誉远中药股份有限公司的主营业务是中药产品的生产与销售。公司的主要产品是龟龄集、定坤丹大蜜丸、定坤丹水蜜丸、定坤丹口服液、安宫牛黄丸、牛黄清心丸、加味龟龄集酒、远字牌龟龄集酒。公司产品先后获得“山西精品”认定,六味地黄丸传统制作技艺及姜炭制作技艺入选晋中市非物质文化遗产名录。","listedPrice":4.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"广誉远(600771)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供广誉远(600771)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"广誉远,600771,广誉远股票,广誉远股票老虎,广誉远股票老虎国际,广誉远行情,广誉远股票行情,广誉远股价,广誉远股市,广誉远股票价格,广誉远股票交易,广誉远股票购买,广誉远股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"广誉远(600771)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供广誉远(600771)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}